Ovid Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, revenue was USD 1.45 million compared to USD 208.38 million a year ago. Net loss was USD 30.7 million compared to net income of USD 160.22 million a year ago. Basic loss per share from continuing operations was USD 0.44 compared to basic earnings per share from continuing operations of USD 2.32 a year ago. Diluted loss per share from continuing operations was USD 0.44 compared to diluted earnings per share from continuing operations of USD 2.3 a year ago.